Scientific name: Lumbrokinase extracted from Eisenia Fetida (earthworms)
supports the fibrinolytic activity of the body, and helps to keep the coagulation system under check and healthy
activates plasminogen
degrades fibrinogen
hydrolyzes fibrin directly
reduces ESR and C-RP
lowers whole blood viscosity & plasma viscosity
decreases plasminogen activator inhibitor (PA1-1)
reduces platelet aggregation
Improves circulatory health in hypercoagulable blood states, which are often associated:
with recent ischemic stroke or a history of ischemic stroke
with history of angina or heart attack
with history of deep venous thrombosis
with stents or artificial heart valves
with cancer, diabetes, chronic fatigue, fibromyalgia, lyme disease
with taking HRT or oral contraceptives
with people receiving EDTA chelation or hyperbaric oxygen therapy
Major advantages:
the only oral fibrinolytic agent being through Phase 1-111 clinical trial(China)
does not significantly affect PT or aPTT
enzyme strength standardized against t-PA & urokinase activities
excellent safety records under mass clinical usage since 1995 in China
Dosage:
acute conditions: 2 capsules 3x per day 30 minutes before each meal for 36 weeks or as recommended by the physician
maintenance: 1 capsule 1-3x per day 30 minutes before each meal
Contra-indications:
recent surgery, lumbar/arterial puncture, or trauma
known aneurysm, G1 ulceration/bleeding, or any bleeding disorders
concurrent administration of strong anti-platelets like Plavix , Ticlid, etc.
known allergy tolumbrokinase or earthworms
The above statements have not been evaluated by the FDA.
This product is not intended to diagnose, treat, cure, or prevent any disease.
Scientific name: Lumbrokinase extracted from Eisenia Fetida (earthworms)
supports the fibrinolytic activity of the body, and helps to keep the coagulation system under check and healthy
activates plasminogen
degrades fibrinogen
hydrolyzes fibrin directly
reduces ESR and C-RP
lowers whole blood viscosity & plasma viscosity
decreases plasminogen activator inhibitor (PA1-1)
reduces platelet aggregation
Improves circulatory health in hypercoagulable blood states, which are often associated:
with recent ischemic stroke or a history of ischemic stroke
with history of angina or heart attack
with history of deep venous thrombosis
with stents or artificial heart valves
with cancer, diabetes, chronic fatigue, fibromyalgia, lyme disease
with taking HRT or oral contraceptives
with people receiving EDTA chelation or hyperbaric oxygen therapy
Major advantages:
the only oral fibrinolytic agent being through Phase 1-111 clinical trial(China)
does not significantly affect PT or aPTT
enzyme strength standardized against t-PA & urokinase activities
excellent safety records under mass clinical usage since 1995 in China
Dosage:
acute conditions: 2 capsules 3x per day 30 minutes before each meal for 36 weeks or as recommended by the physician
maintenance: 1 capsule 1-3x per day 30 minutes before each meal
Contra-indications:
recent surgery, lumbar/arterial puncture, or trauma
known aneurysm, G1 ulceration/bleeding, or any bleeding disorders
concurrent administration of strong anti-platelets like Plavix , Ticlid, etc.
known allergy tolumbrokinase or earthworms
The above statements have not been evaluated by the FDA.
This product is not intended to diagnose, treat, cure, or prevent any disease.
Download the What is Boluoke? Sheet
Download the Boluoke FAQ Sheet
